The Washington Post featured an article on Human Genome Sciences' epic battle to get a drug to market. The story follows a patient who receives an experimental drug for hepatitis in a time that, for HGS, represents "the clearing of its biggest hurdle to date: The Rockville company, now nearly 15 years old, has finally entered the last stage of testing for one of its drugs." (HGS expected to bring another drug, this one for lupus, to the same testing phase in a matter of days.) The article also takes readers on a nostalgic stroll to the beginning of HGS, when founder William Haseltine seemed to investors and (some) pharmaceutical companies like a sure bet. Fifteen years later, those people are holding their breath and hoping that these drugs will turn out to be the wonder they've been awaiting.
HGS, Fifteen Years in Review
Dec 29, 2006
What's Popular?